Unum
UNM
$91.62
-0.74%
Unum Group is a leading provider of group and individual income protection insurance products, operating primarily in the United States, the United Kingdom, and Poland. The company is a dominant player in the U.S. disability insurance market, with a significant portion of its premiums derived from employer-sponsored plans, and it also offers a complementary portfolio of life, long-term care, and other voluntary benefits. The current investor narrative centers on the company's ability to execute a turnaround, with recent news highlighting potential catalysts in share buybacks, premium growth, and margin stabilization following a period of stock price weakness, as the market assesses management's execution against these strategic priorities.…
UNM
Unum
$91.62
Related headlines
Investment Opinion: Should I buy UNM Today?
Rating: Hold. The core thesis is that Unum is a stable, cash-generating insurance company with an attractive forward valuation, but its investment case is currently balanced by significant earnings volatility and technical overextension after a sharp rally.
Supporting Evidence: The recommendation is supported by four key data points. First, the forward P/E of 9.52x is compelling and suggests limited downside if earnings are met. Second, the company generates robust TTM free cash flow of $555.4 million, funding a 2.29% dividend yield. Third, the balance sheet is strong with a debt-to-equity ratio of 0.35. Fourth, analyst consensus EPS of $12.20 implies high conviction in near-term profits, though coverage is limited.
Risks & Conditions: The biggest risks are continued margin volatility and a technical pullback from overbought levels. This Hold rating would upgrade to a Buy if the stock experiences a healthy pullback towards support (e.g., below $85) while forward earnings estimates hold, or if Q4 2025's improved gross margin of 41.62% signals the start of a sustained profitability recovery. It would downgrade to a Sell if revenue growth turns negative or net margin falls below 5%. Relative to its history and mature insurance peers, the stock appears fairly valued, trading at a reasonable P/B of 1.20x and P/S of 1.02x, with the low forward P/E offsetting growth concerns.
Sign up to view all
UNM 12-Month Price Forecast
The outlook for UNM is balanced. The compelling forward valuation and strong cash flow provide downside support, but these are counteracted by stagnant revenue growth and unreliable profitability. The recent powerful rally suggests the market is anticipating a successful turnaround, increasing near-term risk if execution falters. The base case of consolidation around current levels is most probable, as the company works to prove its margin recovery is sustainable. The stance would upgrade to bullish on a pullback to the mid-$80s with intact fundamentals, or on clear evidence of sustained margin expansion. It would turn bearish if the stock breaks below key support on an earnings miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Unum's 12-month outlook, with a consensus price target around $119.11 and implied upside of +30.0% versus the current price.
Average Target
$119.11
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$73 - $119
Analyst target range
Analyst coverage for Unum Group appears limited, with data indicating only 2 analysts providing estimates, which suggests it may be a mid-cap stock with less institutional research focus. This limited coverage can lead to higher volatility and less efficient price discovery. The available data shows consensus estimates for next year's EPS averaging $12.20, with a narrow range from $12.05 to $12.49, indicating high conviction in the earnings forecast among the few covering analysts. The recent institutional ratings from major firms like Morgan Stanley (Equal Weight), Wells Fargo (Overweight), UBS (Neutral), and JP Morgan (Neutral) paint a mixed but generally neutral-to-positive picture, with no outright sell ratings. The pattern of reiterated ratings in early 2026, following the company's Q4 2025 earnings report, suggests analysts are in a 'wait-and-see' mode regarding the company's execution on its strategic priorities of buybacks, growth, and margins.
Bulls vs Bears: UNM Investment Factors
The bull case for Unum is anchored by its strong technical momentum, attractive forward valuation, and robust cash generation, which support shareholder returns. The bear case highlights volatile profitability, stagnant revenue growth, and the risk of a technical reversal after a sharp rally. Currently, the bull side holds stronger evidence, primarily due to the powerful price momentum and compelling forward P/E of 9.52x. The single most important tension in the investment debate is whether the recent earnings volatility and margin compression are temporary issues in a turnaround story, or indicative of a structural problem that the low valuation rightly reflects. The resolution of this profitability trend will be the key determinant of the stock's direction.
Bullish
- Strong Technical Momentum Near Highs: The stock is trading at $92.73, just 0.26% below its 52-week high of $92.97, following a powerful 28.51% surge over the past three months. This breakout, coupled with a 1-month relative strength of +15.37% vs. the SPY, indicates strong, stock-specific buying pressure and positive momentum.
- Attractive Forward Valuation: UNM trades at a forward P/E of 9.52x based on consensus EPS of $12.20, representing a significant discount to its trailing P/E of 18.10x. This low multiple suggests the market is not pricing in aggressive growth expectations, offering a margin of safety if earnings materialize.
- Robust Free Cash Flow Generation: The company generates substantial free cash flow, with TTM FCF of $555.4 million. This strong cash generation supports shareholder returns, including a dividend yield of 2.29%, and provides financial flexibility for strategic initiatives like share buybacks.
- Conservative Balance Sheet: With a low debt-to-equity ratio of 0.35, Unum maintains a strong, conservatively leveraged balance sheet. This financial stability reduces risk during economic downturns and provides capacity for strategic capital deployment.
Bearish
- Volatile and Compressed Profitability: Net income and margins show significant quarterly volatility. Q4 2025 net margin was 5.37%, down sharply from 10.89% in Q4 2024, and the Q3 2025 net margin was just 1.18%. This inconsistency raises concerns about earnings quality and predictability.
- Stagnant Revenue Growth: Revenue growth is anemic, with Q4 2025 revenue of $3.24 billion representing only a 1.25% year-over-year increase. Furthermore, revenue declined sequentially from $3.36 billion in Q3 2025, highlighting a lack of top-line momentum.
- Technically Overextended Near Resistance: Trading at the very top of its 52-week range after a sharp 15.29% one-month rally, the stock is technically overextended. A failure to break above the $92.97 resistance could trigger a significant pullback, with the 52-week low at $68.28 representing a -26% downside.
- Limited Analyst Coverage and Sentiment: With only 2 analysts providing estimates, UNM suffers from limited institutional research coverage, which can lead to less efficient price discovery and higher volatility. Recent institutional ratings are mixed (Equal Weight, Overweight, Neutral), indicating a lack of strong conviction.
UNM Technical Analysis
The stock is in a strong, sustained uptrend, having gained 17.01% over the past year and currently trading at the very top of its 52-week range, just 0.26% below its 52-week high of $92.97. This positioning near the highs suggests significant positive momentum but also raises the risk of a near-term pullback or consolidation as the stock becomes technically overextended. Recent momentum has been exceptionally strong, with the stock surging 15.29% over the past month and 28.51% over the past three months, significantly outpacing the broader market, as evidenced by a 1-month relative strength of +15.37% versus the SPY. This acceleration from the longer-term trend indicates powerful buying pressure and a potential breakout phase. Key technical levels are clear, with immediate resistance at the 52-week high of $92.97 and support at the 52-week low of $68.28. A confirmed breakout above $92.97 could signal a continuation of the uptrend, while a failure and reversal could see a test of lower support levels. The stock's beta of 0.246 indicates it is far less volatile than the market, which is unusual for such a strong price move and suggests the recent surge may be driven by stock-specific catalysts rather than broad market sentiment.
Beta
0.25
0.25x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$68-$93
Price range past year
Annual Return
+17.7%
Cumulative gain past year
| Period | UNM Return | S&P 500 |
|---|---|---|
| 1m | +10.7% | +0.3% |
| 3m | +25.6% | +12.3% |
| 6m | +15.6% | +8.9% |
| 1y | +17.7% | +24.0% |
| ytd | +18.6% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNM Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $3.24 billion representing a 1.25% year-over-year increase; however, this masks significant quarterly volatility, as revenue declined sequentially from $3.36 billion in Q3 2025. The Unum USA segment, generating $3.96 billion, is the primary revenue driver, while the Colonial Life and International segments contribute smaller amounts. Profitability is stable but has shown some compression; the company reported net income of $174.1 million in Q4 2025, with a net margin of 5.37%, which is down from the 10.89% net margin in Q4 2024. The gross margin for Q4 2025 was 41.62%, a significant improvement from the 21.99% in Q3 2025, indicating potential recovery in underwriting or investment income, though quarterly results are inconsistent. The balance sheet is conservatively managed with a low debt-to-equity ratio of 0.35, indicating minimal financial leverage. The company generates substantial free cash flow, with TTM free cash flow of $555.4 million, providing ample liquidity for shareholder returns and investments. Return on equity (ROE) stands at 6.64%, which is modest but positive, reflecting the steady, capital-intensive nature of the insurance business.
Quarterly Revenue
$3.2B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.41%
Latest Quarter
Free Cash Flow
$555400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNM Overvalued?
Given the company's consistent profitability, the primary valuation metric is the Price-to-Earnings (P/E) ratio. Unum trades at a trailing P/E of 18.10x and a forward P/E of 9.52x based on estimated EPS of $12.20. The substantial discount of the forward P/E suggests the market expects a significant earnings increase in the coming year. Compared to its own historical range, the current trailing P/E of 18.10x is above the lower end seen in recent years (e.g., 4.29x in Q3 2024) but below peaks above 80x during periods of low earnings, placing it in a mid-range historically. This suggests the market is pricing in improved, normalized earnings rather than peak optimism or deep pessimism. The stock trades at a Price-to-Sales (P/S) ratio of 1.02x and a Price-to-Book (P/B) ratio of 1.20x, both of which are reasonable for a mature insurance company, indicating the market is not assigning a significant growth premium to the sales or asset base.
PE
18.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~83x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Unum faces significant earnings volatility, with net margin collapsing from 10.89% in Q4 2024 to 5.37% in Q4 2025, and a low of 1.18% in Q3 2025. This inconsistency makes forecasting difficult and suggests potential underlying issues in claims management or investment income. While revenue growth is modest at 1.25% YoY, the sequential decline from Q3 to Q4 2025 indicates potential stagnation in its core U.S. disability market. The company's dependence on continued share buybacks and margin stabilization to drive EPS growth, as highlighted in recent news, creates execution risk if management fails to deliver.
Market & Competitive Risks: The stock's recent 28.51% 3-month surge has pushed it to the top of its 52-week range, increasing valuation compression risk if the earnings recovery narrative falters. While its forward P/E of 9.52x appears cheap, it trades at a premium to its book value (P/B of 1.20x) and may be sensitive to rising interest rates impacting its investment portfolio. The stock's low beta of 0.246 suggests it is less correlated to the market, but the recent surge appears driven by stock-specific catalysts, making it vulnerable to sentiment shifts if those catalysts disappoint. As a dominant player in a mature market, competitive pressure on pricing and product innovation presents a persistent headwind.
Worst-Case Scenario: The most damaging scenario would involve a failure to stabilize margins, leading to a significant earnings miss against the $12.20 EPS consensus. This, combined with a technical reversal from overbought levels, could trigger analyst downgrades and a rapid de-rating. A realistic downside could see the stock re-test its 52-week low of $68.28, which represents a -26% decline from the current price of $92.73. Such a move would be consistent with the stock's historical max drawdown of -16.57% observed in the recent data, potentially exacerbated by the low trading volume and limited analyst coverage.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: Sharp declines in net margin, as seen from 10.89% to 5.37% YoY, make future profits unpredictable. 2) Technical Reversal Risk: After a 28.51% 3-month surge to the top of its range, the stock is overextended and vulnerable to a pullback; a drop to the 52-week low of $68.28 represents -26% downside. 3) Growth Stagnation Risk: Anemic 1.25% YoY revenue growth and sequential declines indicate a lack of top-line momentum. 4) Limited Coverage Risk: With only 2 analyst estimates, the stock may experience higher volatility and less efficient price discovery.
The 12-month forecast presents three scenarios with associated probabilities. The Base Case (60% probability) sees the stock trading between $85 and $95, assuming the company meets the $12.20 EPS consensus with stable margins. The Bull Case (25% probability) projects a breakout to $100-$110 on successful execution of the turnaround, including sustained margin recovery. The Bear Case (15% probability) warns of a decline to $68-$75 if earnings disappoint and the technical breakout fails. The base case is most likely, implying the recent rally may lead to consolidation rather than continued sharp appreciation in the near term.
UNM's valuation sends mixed signals but leans towards fair value. Its forward P/E of 9.52x is very low and suggests undervaluation if earnings estimates are reliable. However, its trailing P/E of 18.10x and Price-to-Book ratio of 1.20x are reasonable for a mature insurer and do not scream cheap. The market appears to be pricing in low growth expectations (evident in the forward P/E discount) and skepticism about earnings sustainability. Compared to its own volatile history and sector peers, UNM is fairly valued, trading at a modest premium to book value while offering a below-market earnings multiple.
UNM presents a mixed risk/reward profile at its current price near 52-week highs. For value-oriented, income-seeking investors, its forward P/E of 9.52x and 2.29% dividend yield are attractive, and its strong free cash flow provides stability. However, the sharp 28.51% rally over three months has likely priced in near-term optimism, and the stock's volatile profitability (net margin fell from 10.89% to 5.37% YoY) adds risk. It could be a good buy for patient investors on a pullback, but entering at current levels carries heightened risk of a technical reversal.
UNM is more suitable for a long-term investment horizon. As a low-beta (0.246), dividend-paying stock in a mature industry, it is not ideal for short-term trading, especially after its recent sharp rally. Long-term investors can benefit from the compounding dividend and potential valuation normalization if the turnaround narrative plays out over several quarters. The stock's low volatility provides stability for a portfolio, but its modest growth profile means significant capital appreciation requires patience. A minimum holding period of 2-3 years is suggested to ride out quarterly earnings volatility and allow the strategic initiatives to bear fruit.